
Opinion|Videos|November 8, 2024
Looking Ahead: Anticipating Changes in Lupus Guidelines and Clinical Practice
Author(s)Amit Saxena, MD
Key Takeaways
- Individual patient characteristics, such as disease severity and comorbidities, significantly influence lupus nephritis treatment decisions.
- Steroid use requires careful balancing to maximize efficacy while minimizing adverse effects in lupus nephritis management.
Amit Saxena, MD, discusses how personalized treatment decisions for lupus nephritis require careful consideration of patient characteristics, multidisciplinary coordination, and emerging guidelines, while acknowledging both the opportunities and challenges that lie ahead in clinical practice.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What considerations (eg, individual patient characteristics, steroid use, drug interactions) guide your treatment choices for managing lupus nephritis?
- How important is multidisciplinary care in managing lupus nephritis, and how do you coordinate this?
- The ACR is working on a 2-part lupus guideline project expected next year. In what ways do you see these guidelines evolving in the future?
- What specific opportunities or challenges do you see on the horizon for managing lupus nephritis in practice?
Advertisement
Related to this article

Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.

Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.

Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.

Low awareness that fatty liver can silently progress and that MASH fibrosis is treatable drives missed follow-up testing, says Rohit Loomba, MD.

The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
Advertisement
Advertisement
Trending on AJMC
1
ObesityWeek 2026: Studies Map GLP-1 Access Gaps, Obesity's Costs
2
FDA Approves Durvalumab Plus EV Before Surgery in Cisplatin-Ineligible MIBC
3
MM’s Vulnerability to CAR T Was a Happy Surprise: Nikhil C. Munshi, MD
4
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
5


